Zoetis Inc. (NYSE:ZTS) Shares Sold by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,485 shares of the company’s stock after selling 2,219 shares during the period. Orion Portfolio Solutions LLC’s holdings in Zoetis were worth $11,622,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the third quarter worth approximately $31,000. First Personal Financial Services acquired a new stake in Zoetis during the 3rd quarter worth $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis during the 3rd quarter worth $33,000. Quarry LP grew its holdings in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares in the last quarter. Finally, Fortitude Family Office LLC raised its position in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after buying an additional 222 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS opened at $176.46 on Friday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The stock’s fifty day moving average is $182.07 and its two-hundred day moving average is $181.00. The company has a market capitalization of $79.61 billion, a P/E ratio of 33.17, a P/E/G ratio of 2.88 and a beta of 0.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.36 EPS. Equities analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st were issued a $0.432 dividend. The ex-dividend date of this dividend was Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. Zoetis’s dividend payout ratio is currently 32.52%.

Analyst Ratings Changes

ZTS has been the topic of a number of recent research reports. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $219.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.